|
Friday, November 19, 2021
Print Current Session:
 |
|
|
Friday
SESSION 93:
NEW DEVELOPMENTS IN MEDICAL AND DRUG TREATMENTS: BEST ANTIPLATELET REGIMENS; UPDATE ON RARE VASCULAR DISEASES
|
|
| SESSION 93 SCHEDULE | |
| ANTIPLATELET REGIMENS | |
| 2:36 PM - 2:41 PM | Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs |
|
Presenter(s):David H. Stone, MD Location: Grand Ballroom West, 3rd Floor |
|
| 2:42 PM - 2:47 PM | Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE |
|
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
| 2:48 PM - 2:53 PM | Most Effective Antiplatelet After Lower Extremity Interventional Treatments For CLTI – POBA, DCBs, Stents, Etc. |
|
Presenter(s):Maciej L. Dryjski , MD, PhD Location: Grand Ballroom West, 3rd Floor |
|
| 2:54 PM - 2:59 PM | Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem |
|
Presenter(s):Karthikeshwar Kasirajan, MD Location: Grand Ballroom West, 3rd Floor |
|
| NEW DEVELOPMENTS IN LIPID MANAGEMENT – STATINS | |
| 3:00 PM - 3:05 PM | Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Shockingly These Treatments Are Underutilized – Especially In Women: Why Is This So |
|
Presenter(s):Christian A. Behrendt, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:06 PM - 3:11 PM | Value Of Statins In AAA Patients After Repair: Long-Term Impact On Mortality |
|
Presenter(s):Adam Beck, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:12 PM - 3:17 PM | The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help |
|
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC Location: Grand Ballroom West, 3rd Floor |
|
| 3:18 PM - 3:24 PM | Panel Discussion |
| 3:24 PM - 3:29 PM | Elevated Neutrophil To Lymphocyte Ratio Predicts Poor Outcomes And Mortality After Elective EVAR And CEA: What Is The Mechanism |
|
Presenter(s):Jae S. Cho, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:30 PM - 3:35 PM | The Justification For Carotid Screening Is To Promote Medical Treatment To Decrease Stroke And MI Risks, Not To Push Patients To Have Unnecessary Invasive Procedures |
|
Presenter(s):Kosmas I. Paraskevas, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:36 PM - 3:41 PM | Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: Doing These Things Should Be A Lifetime Goal |
|
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
| 3:42 PM - 3:47 PM | Current (2020) Status Of Diagnosis And Treatment Of Buerger’s Disease: Does It Exist Or Is It Just A Variant Of Atherosclerosis |
|
Presenter(s):Kamphol Laohapensang, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:48 PM - 3:53 PM | How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well |
|
Presenter(s):James H. Black, III, MD Location: Grand Ballroom West, 3rd Floor |
|
| 3:54 PM - 4:00 PM | Panel Discussion |
| END OF SESSION 93 | |
| previous | next |